16.75p-0.75 (-4.29%)20 Dec 2024, 14:22
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Skinbiotherapeutics PLC Fundamentals

Company NameSkinbiotherapeutics PLCLast Updated2024-12-20
IndustryBiotechnologySectorHealthcare
Shares in Issue228.436 mMarket Cap£38.26 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.02EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1570Debt Equity Ratio0.0134
Asset Equity Ratio1.7560Cash Equity Ratio0.2697
Quick Ratio0.6328Current Ratio0.93
Price To Book Value13.4590ROCE0

Skinbiotherapeutics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Skinbiotherapeutics PLC Company Financials

Assets2024202320222021
Tangible Assets£116,369.00£173,160.00£126,903.00£143,328.00
Intangible Assets£3.43 m£700,331.00£625,504.00£528,941.00
Investments0000
Total Fixed Assets£3.54 m£873,491.00£752,407.00£672,269.00
Stocks£472,419.00£33,497.00£122,571.000
Debtors£341,154.00£13,509.00£12,901.00£10,000.00
Cash & Equivalents£800,904.00£1.31 m£1.80 m£4.61 m
Other Assets0000
Total Assets£5.22 m£2.59 m£3.08 m£5.73 m
Liabilities2024202320222021
Creditors within 1 year£1.80 m£529,741.00£508,959.00£404,894.00
Creditors after 1 year£440,485.00£69,601.00£100,647.00£114,780.00
Other Liabilities0000
Total Liabilities£2.25 m£599,342.00£609,606.00£519,674.00
Net assets£2.97 m£1.99 m£2.48 m£5.22 m
Equity2024202320222021
Called up share capital£2.02 m£1.73 m£1.57 m£1.57 m
Share Premium£14.51 m£10.95 m£8.76 m£8.76 m
Profit / Loss-£2.95 m-£3.01 m-£2.99 m-£1.50 m
Other Equity£2.97 m£1.99 m£2.48 m£5.22 m
Preference & Minorities0000
Total Capital Employed£2.97 m£1.99 m£2.48 m£5.22 m
Ratios2024202320222021
Debt Ratio£0.01£0.03£0.04£0.02
Debt-to-Equity£0.01£0.03£0.04£0.02
Assets / Equity1.75601.75601.75601.7560
Cash / Equity0.26970.26970.26970.2697
EPS-£0.02-£0.02-£0.02-£0.01
Cash Flow2024202320222021
Cash from operating activities-£2.73 m-£2.65 m-£2.67 m-£1.56 m
Cashflow before financing£1.79 m-£327,812.00-£2.71 m£2.56 m
Increase in Cash-£510,930.00-£493,089.00-£2.80 m£2.45 m
Income2024202320222021
Turnover£1.21 m£132,057.00£74,761.000
Cost of sales£525,631.00£46,867.00£29,424.000
Gross Profit£683,038.00£85,190.00£45,337.000
Operating Profit-£2.91 m-£3.00 m-£2.98 m-£1.50 m
Pre-Tax profit-£2.95 m-£3.01 m-£2.99 m-£1.50 m

Skinbiotherapeutics PLC Company Background

SectorHealthcare
ActivitiesSkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
Latest Interim Date22 Mar 2024
Latest Fiscal Year End Date4 Dec 2024

Skinbiotherapeutics PLC Directors

AppointedNamePosition
2022-04-29Mr. Douglas John QuinnExecutive Director,Chief Financial Officer and Company Secretary
2024-12-10Mr. Martin Braddock Hunt Non-Executive Director,Chairman
2020-12-04Dr. Catherine Anne O'Neill Executive Director,Chief Executive Officer
2024-12-10Dr. Catherine Denise Prescott Non-Executive Director
2024-12-10Mr. Stuart John Ashman Executive Director,Chief Executive Officer
2024-12-10Mr. Manprit Singh RandhawaExecutive Director,Chief Financial Officer and Company Secretary
2024-12-10Ms. Danielle BekkerNon-Executive Director

Skinbiotherapeutics PLC Contact Details

Company NameSkinBioTherapeutics PLC
Address15 Silk House, Park Green, Macclesfield, SK11 7QJ
Telephone+44 1614682760
Websitehttps://www.skinbiotherapeutics.com

Skinbiotherapeutics PLC Advisors

AuditorJeffreys Henry LLP
Phone+44 2073092222
Fax+44 2073092309
Financial PR AdviserInstinctif Partners
Phone+44 2074572020
Fax+44 2078667900
Solicitorturnerparkinson LLP
RegistrarShare Registrars Limited
Phone+44 1252821390
Fax+44 1252719232
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880
StockbrokerTurner Pope Investments (TPI) Ltd
Phone+44 2036214120